Worldwide: M&A/Private Equity

The FTC has filed an amicus brief challenging Amgen's acquisition of pending patent applications for Enbrel, arguing that such strategic purchases can constitute anticompetitive conduct under antitrust law. This intervention signals heightened regulatory scrutiny of pharmaceutical companies that acquire third-party patent applications to extend drug monopolies and block biosimilar competition. The Fourth Circuit's ruling could fundamentally reshape how life sciences companies structure patent portfolio tran

On August 20, 2026, the Small Business Administration (SBA) proposed to materially amend the way it establishes size standards for purposes of federal procurement.

When a buyer and seller agree on a purchase price, many people assume the hard part of the negotiation is over. In reality, some of the most consequential decisions in any M&A transaction are made after the headline number is set—starting with the fundamental question of deal structure.